Literature DB >> 10817583

Brain MRI lesions and atrophy are related to depression in multiple sclerosis.

R Bakshi1, D Czarnecki, Z A Shaikh, R L Priore, V Janardhan, Z Kaliszky, P R Kinkel.   

Abstract

It is unclear whether brain MRI lesions are associated with depression in multiple sclerosis (MS). Neurological dysfunction in depressed (n= 19) and non-depressed (n = 29) MS patients was rated by expanded disability status scale (EDSS). EDSS was weakly predictive of the presence of (p = 0.03) and severity of (p = 0.01) depression. After correcting for EDSS, the presence of depression was predicted by superior frontal and superior parietal hypointense TI lesions (p<0.01); the severity of depression was predicted by superior frontal, superior parietal and temporal TI lesions, lateral and third ventricular enlargement, and frontal atrophy (p<0.01). Depression was not related to bright T2 lesions or enhancement. We conclude that atrophy and cortical-subcortical disconnection due to frontal and parietal white matter destructive lesions may contribute to depression in MS.

Entities:  

Mesh:

Year:  2000        PMID: 10817583     DOI: 10.1097/00001756-200004270-00003

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  55 in total

1.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 2.  Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials.

Authors:  Frederik Barkhof
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Authors:  Stefan M Gold; Kyle C Kern; Mary-Frances O'Connor; Michael J Montag; Aileen Kim; Ye S Yoo; Barbara S Giesser; Nancy L Sicotte
Journal:  Biol Psychiatry       Date:  2010-06-19       Impact factor: 13.382

4.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

5.  Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.

Authors:  Irit Gil-Ad; Ben H Amit; Liat Hayardeni; Igor Tarasenko; Michal Taler; Ravit Uzan Gueta; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2014-07-27       Impact factor: 3.444

6.  Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Authors:  Tomas Uher; Kelly Fellows; Dana Horakova; Robert Zivadinov; Manuela Vaneckova; Lukas Sobisek; Michaela Tyblova; Zdenek Seidl; Jan Krasensky; Niels Bergsland; Bianca Weinstock-Guttman; Eva Havrdova; Murali Ramanathan
Journal:  J Lipid Res       Date:  2016-12-06       Impact factor: 5.922

7.  Visual assessment of brain magnetic resonance imaging detects injury to cognitive regulatory sites in patients with heart failure.

Authors:  Alan Pan; Rajesh Kumar; Paul M Macey; Gregg C Fonarow; Ronald M Harper; Mary A Woo
Journal:  J Card Fail       Date:  2013-02       Impact factor: 5.712

Review 8.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

9.  Normalized regional brain atrophy measurements in multiple sclerosis.

Authors:  Robert Zivadinov; Laura Locatelli; Barbara Stival; Alessio Bratina; Attilio Grop; Davide Nasuelli; Ozana Brnabic-Razmilic; Marino Zorzon
Journal:  Neuroradiology       Date:  2003-10-10       Impact factor: 2.804

Review 10.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.